Saeid Alinezhad
Overview
Explore the profile of Saeid Alinezhad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Srinivasan S, Kryza T, Bock N, Tse B, Sokolowski K, Janaththani P, et al.
Nat Commun
. 2024 Nov;
15(1):9587.
PMID: 39505858
Genetic variation at the 19q13.3 KLK locus is linked with prostate cancer susceptibility in men. The non-synonymous KLK3 single nucleotide polymorphism (SNP), rs17632542 (c.536 T > C; Ile163Thr-substitution in PSA)...
2.
Thomas P, Alinezhad S, Joshi A, Sweeney K, Tse B, Tevz G, et al.
Curr Oncol
. 2023 Nov;
30(11):9437-9447.
PMID: 37999103
Patient-derived xenograft (PDX) models have been established as important preclinical cancer models, overcoming some of the limitations associated with the use of cancer cell lines. The utility of prostate cancer...
3.
Srinivasan S, Kryza T, Bock N, Tse B, Sokolowski K, Panchadsaram J, et al.
Res Sq
. 2023 Apr;
PMID: 37034758
Genetic variation at the 19q13.3 locus is linked with prostate cancer susceptibility. The non-synonymous SNP, rs17632542 (c.536T>C; Ile163Thr-substitution in PSA) is associated with reduced prostate cancer risk, however, the functional...
4.
Thomas P, Perera M, Alinezhad S, Joshi A, Saadat P, Nicholls C, et al.
J Vis Exp
. 2022 Jan;
(178).
PMID: 35037658
Current in vitro therapeutic testing platforms lack relevance to tumor pathophysiology, typically employing cancer cell lines established as two-dimensional (2D) cultures on tissue culture plastic. There is a critical need...
5.
Joshi A, Roberts M, Alinezhad S, Williams E, Vela I
BJU Int
. 2020 May;
126(1):65-72.
PMID: 32383524
Objective: To provide a clinically relevant outline of various current precision medicine principles and available evidence on the application and potential for a precision medicine approach in prostate cancer. Methods:...
6.
Montoya Perez I, Jambor I, Pahikkala T, Airola A, Merisaari H, Saunavaara J, et al.
J Magn Reson Imaging
. 2019 Oct;
51(5):1540-1553.
PMID: 31588660
Background: Accurate risk stratification of men with a clinical suspicion of prostate cancer (cSPCa) remains challenging despite the increasing use of MRI. Purpose: To evaluate the diagnostic accuracy of a...
7.
Alinezhad S, Vaananen R, Mattsson J, Li Y, Tallgren T, Tong Ochoa N, et al.
PLoS One
. 2016 Jun;
11(6):e0158255.
PMID: 27327298
[This corrects the article DOI: 10.1371/journal.pone.0155901.].
8.
Alinezhad S, Vaananen R, Mattsson J, Li Y, Tallgren T, Tong Ochoa N, et al.
PLoS One
. 2016 May;
11(5):e0155901.
PMID: 27196083
The identification and validation of biomarkers for clinical applications remains an important issue for improving diagnostics and therapy in many diseases, including prostate cancer. Gene expression profiles are routinely applied...
9.
Alinezhad S, Vaananen R, Tong Ochoa N, Vertosick E, Bjartell A, Bostrom P, et al.
BMC Urol
. 2016 Mar;
16:10.
PMID: 26928323
Background: The high false negative rates for initial prostate biopsies refer a large number of the men for repeat biopsies each year. Therefore, biomarkers associated with high risk of the...
10.
Alinezhad S, Vaananen R, Tallgren T, Montoya Perez I, Jambor I, Aronen H, et al.
Urol Oncol
. 2016 Feb;
34(6):255.e15-22.
PMID: 26857646
Background: The aim of the study was to evaluate the diagnostic power of molecular markers in men with a clinical suspicion of prostate cancer (PCa) using apparently benign areas as...